{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-116657","form_type":"8-K","ticker":"CYPH","cik":"0001509745","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.312014+00:00","generated_at":"2026-06-08T04:59:43.884149+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Leap Therapeutics Q3 net loss $13.7M; DKN-01 colorectal study expands to Part B","bullets":["Net loss $13.7M in Q3 2023 vs $15.1M in Q3 2022; cash and equivalents $80.7M.","DKN-01 DeFianCe Part A met >20% ORR threshold; Part B with 130 patients now enrolling; data at Jan 2024 med conf.","DisTinGuish gastric cancer Part C enrollment expected by end 2023; prior data showed 73% ORR, 19.5 mo OS.","R&D expenses $11.5M vs $12.1M; G&A $3.3M vs $3.2M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-116657","json":"https://secwatch.observer/filing/0001104659-23-116657.json","markdown":"https://secwatch.observer/filing/0001104659-23-116657.md","text":"https://secwatch.observer/filing/0001104659-23-116657.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923116657/0001104659-23-116657-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923116657/tm2330433d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:59:43.884149+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"57f2c20d5ed4adaa6b51acb89250a414edb83c54","claim":"CYPHERPUNK TECHNOLOGIES INC. reported the third quarter ended September 30, 2023 results: net income Net Loss was $13.7 million.","evidence_excerpt":"Net Loss was $13.7 million for the third quarter 2023, compared to $15.1 million for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923116657/0001104659-23-116657-index.htm","confidence":0.97,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Net income","value":"Net Loss was $13.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}